title: Isoforms of p38MAPK gamma and delta contribute to differentiation of human AML cells induced by 1,25-dihydroxyvitamin D₃.
abstract: Inhibition of p38MAPK alpha/beta is known to enhance 1,25-dihydroxyvitamin (1,25D)-induced monocytic differentiation, but the detailed mechanism of this effect was not clear. We now show that the enhancement of differentiation becomes apparent with slow kinetics (12-24 h). Interestingly, the inhibition of p38MAPK alpha/beta by their selective inhibitor SB202190 (SB) leads to an upregulated expression of p38MAPK isoforms gamma and delta in 1,25D-treated AML cells, in cell lines and in primary culture. Although the expression and activating phosphorylations of p38MAPK alpha are also increased by an exposure of the cells to SB, its kinase activity is blocked by SB, as shown by reduced levels of phosphorylated Hsp27, a downstream target of p38MAPK alpha. A positive role of p38MAPKs in 1,25D-induced differentiation is shown by the inhibition of differentiation by antisense oligonucleotides to all p38MAPK isoforms. Other principal branches of MAPK pathways showed early (6 h) activation of MEK/ERK by SB, followed by activation of JNK1/2 pathway and enhanced expression and/or activation of PU.1, ATF-2 differentiation-related transcription factors. Taken together with previous reports, the results indicate that 1,25D-induced differentiation is enhanced by the activation of at least three branches of MAPK pathways (ERK1/2; p38MAPK gamma/delta; JNK1/2). This activation may result from the removal of feedback inhibition of an upstream regulator of those pathways, when p38MAPK alpha and beta are inhibited by SB.
authors.affiliation: Department of Pathology and Laboratory Medicine, UMDNJ-New Jersey, Medical School, Newark, NJ 07103, USA.
authors.forename: Jing
authors.initials: J
authors.lastname: Zhang
authors.forename: Jonathan S
authors.initials: JS
authors.lastname: Harrison
authors.forename: George P
authors.initials: GP
authors.lastname: Studzinski
mesh_terms: D000943:Antigens, Differentiation / Q000235:genetics / Q000378:metabolism; D002117:Calcitriol / Q000494:pharmacology*; D002454:Cell Differentiation / Q000187:drug effects* / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D018922:HL-60 Cells; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D007527:Isoenzymes / Q000235:genetics / Q000378:metabolism / Q000502:physiology; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D048291:Mitogen-Activated Protein Kinase 12 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D048292:Mitogen-Activated Protein Kinase 13 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D013997:Time Factors; D020298:U937 Cells
chemical_list: D000943:Antigens, Differentiation; D007093:Imidazoles; D007527:Isoenzymes; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D048291:Mitogen-Activated Protein Kinase 12; D048292:Mitogen-Activated Protein Kinase 13; D002117:Calcitriol; C090942:4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole
references.citation: FEBS Lett. 1996 Sep 2;392(3):209-14
references.pmid: 8774846
references.citation: Proc Soc Exp Biol Med. 1985 Jul;179(3):288-95
references.pmid: 3858884
references.citation: J Biol Chem. 1996 Feb 9;271(6):2886-91
references.pmid: 8621675
references.citation: J Cell Biochem. 2001 Apr 2-27;82(1):68-77
references.pmid: 11400164
references.citation: J Cell Biol. 1984 Feb;98(2):391-8
references.pmid: 6319426
references.citation: J Biol Chem. 1996 Jul 26;271(30):17920-6
references.pmid: 8663524
references.citation: Exp Cell Res. 2010 Feb 15;316(4):603-14
references.pmid: 19945455
references.citation: Int J Cancer. 1976 May 15;17(5):565-77
references.pmid: 178611
references.citation: Mol Cell Biol. 2005 May;25(9):3670-81
references.pmid: 15831472
references.citation: J Biol Chem. 2004 Jun 11;279(24):25345-52
references.pmid: 15056660
references.citation: Blood. 1979 Sep;54(3):713-33
references.pmid: 288488
references.citation: Cancer Treat Rep. 1985 Dec;69(12):1399-407
references.pmid: 2416438
references.citation: Cancer Res. 2006 Apr 15;66(8):4402-9
references.pmid: 16618766
references.citation: Hematol Oncol. 2010 Sep;28(3):124-32
references.pmid: 19866452
references.citation: Proc Natl Acad Sci U S A. 1981 Aug;78(8):4990-4
references.pmid: 6946446
references.citation: Crit Rev Clin Lab Sci. 2009;46(4):190-209
references.pmid: 19650715
references.citation: Biochemistry. 1998 Sep 29;37(39):13846-53
references.pmid: 9753474
references.citation: J Steroid Biochem Mol Biol. 2005 Oct;97(1-2):47-55
references.pmid: 16046262
references.citation: Endocrinology. 2002 Jul;143(7):2508-14
references.pmid: 12072382
references.citation: Curr Opin Cell Biol. 1996 Apr;8(2):205-15
references.pmid: 8791420
references.citation: Leuk Res. 1995 Jan;19(1):65-72
references.pmid: 7837819
references.citation: Neurochem Res. 2000 Apr;25(4):527-31
references.pmid: 10823586
references.citation: J Biol Chem. 1993 Mar 5;268(7):5014-20
references.pmid: 8095266
references.citation: Cancer Res. 1999 May 1;59(9):2195-202
references.pmid: 10232608
references.citation: Curr Biol. 1998 Sep 24;8(19):1049-57
references.pmid: 9768359
references.citation: FEBS Lett. 2000 Apr 21;472(1):50-2
references.pmid: 10781803
references.citation: J Leukoc Biol. 1998 Sep;64(3):409-17
references.pmid: 9738669
references.citation: Anticancer Res. 2001 Jan-Feb;21(1A):499-504
references.pmid: 11299787
references.citation: Anticancer Agents Med Chem. 2010 Mar;10(3):186-95
references.pmid: 20015009
references.citation: J Biol Chem. 2002 Oct 4;277(40):37212-8
references.pmid: 12149242
references.citation: J Biol Chem. 2003 Jul 18;278(29):26715-21
references.pmid: 12738796
references.citation: Cytometry. 1992;13(8):795-808
references.pmid: 1333943
references.citation: Leuk Res. 2010 May;34(5):553-65
references.pmid: 19811822
references.citation: Pharmacol Ther. 1999 May-Jun;82(2-3):389-97
references.pmid: 10454214
references.citation: J Biol Chem. 1997 Sep 19;272(38):23668-74
references.pmid: 9295308
references.citation: Exp Cell Res. 2007 May 1;313(8):1722-34
references.pmid: 17397830
references.citation: Cell Signal. 2000 Jan;12(1):1-13
references.pmid: 10676842
references.citation: Biochim Biophys Acta. 2000 Oct 18;1502(2):207-23
references.pmid: 11040446
references.citation: J Cell Biochem. 2001;80(4):471-82
references.pmid: 11169731
references.citation: J Cell Biochem. 2003 Aug 15;89(6):1087-101
references.pmid: 12898508
references.citation: J Steroid Biochem Mol Biol. 2005 Oct;97(1-2):195-202
references.pmid: 16085411
references.citation: Biochem Biophys Res Commun. 1999 Sep 24;263(2):528-36
references.pmid: 10491326
references.citation: Leukemia. 2005 Oct;19(10):1812-7
references.pmid: 16107889
references.citation: J Steroid Biochem Mol Biol. 2007 Jun-Jul;105(1-5):140-9
references.pmid: 17583492
references.citation: EMBO J. 1996 Dec 16;15(24):7026-35
references.pmid: 9003778
references.citation: Cell Signal. 2005 Dec;17(12):1572-7
references.pmid: 15951157
references.citation: Exp Cell Res. 2000 Aug 1;258(2):425-37
references.pmid: 10896794
references.citation: J Biol Chem. 1997 Nov 28;272(48):30122-8
references.pmid: 9374491
references.citation: Cancer Biol Ther. 2010 Aug 15;10(4):344-50
references.pmid: 20543580
references.citation: Cancer Res. 2004 Jan 1;64(1):370-7
references.pmid: 14729647
references.citation: Anal Biochem. 1987 Apr;162(1):156-9
references.pmid: 2440339